In addition, we assume that sensitivity to BTZ treatment depends on the “mature” differentiation status of MM cells reflected by the levels of IRE1α and the transcription factor sXBP1 and that GRP78-mediated UPR has no impact on response to BTZ. This evidence concerns the gene CASC3 and Miyoshi myopathy.